-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Reporters learned yesterday that international pharmaceutical giant Pfizer on December 7 with the United States BioAtla signed a 1 billion U.S. dollars strategic licensing and options agreement, the two sides will jointly promote the development and commercialization of a new class of antibody therapies. It is worth noting that the funds of Beida Ernest Bioengineering Group Co., Ltd. (the "Unde named Group") are the largest institutional shareholders of BioAtla. At the same time, the Undered Group has signed an exclusive cooperation agreement with BioAtla for the Chinese market. With the antibody drug on the market, the undelievered group will receive a double harvest from equity investment and product sales. "Antibody drug research and development and industrial investment has been the focus of the domestic and foreign pharmaceutical market, the undelievered group has such a business opportunity, quite vision and courage." Some senior industry insiders said so.
On December 7, BioAtla (also known as "San Diego Biotech") and Pfizer entered into a strategic licensing and option agreement for new antibody therapy, which combines BioAtla's conditional active biologic agent (CAB) antibodies with the payload of Pfizer's patented antibody drug ADC, which is licensed to use BioAtla to target CAB immunosuppressants for CTLA-4. If successful, BioAtla's technology will achieve the goal of targeting CTLA4, which is locally present in tumor micro-environments and expressed in immune cells. Both BioAtla and Pfizer are eligible for installments and royalties, including options and licenses for CTLA4, based on each CAB-ADC antibody option developed and commercialized by the other party. In addition, BioAtla is eligible for up-payments, regulatory and sales phased payments totalling approximately $1 billion, as well as double-digit tiered marginal usage fees based on potential future product sales.
founded in 2007, BioAtla is a global biotech company with more than 100 published and pending patents, including platform technologies representing its full range of therapeutic protein development capabilities. And the company's patented CAB platform represents a disruptive technology, relying on the technology developed the fourth generation of antibody drugs are now in the first phase of clinical, will become the world's top antibody drugs.
It is worth noting that the institutional shareholder behind BioAtla is Shanghai Weihua Investment Center (Limited Partnership), a fund owned by the undet named group, which was set up in April to invest in BioAtla, with a total of $30m invested in BioAtla, which resulted in a 20 per cent stake in BioAtla. BioAtla is understood to be expected to list on NASDAQ next year.
Yesterday, Huang Jiangnan, general counsel of financial planning of the undecided group, told reporters that the undecided group not only participated in BioAtla's equity investment through its uninsisted investment center, but also signed an exclusive cooperation agreement with the company for the Chinese market, the undecided group will be BioAtla developed antibody drugs in China clinical trials, tissue production, and BioAtla in the U.S. Drug Administration simultaneously apply for listing approval. With the antibody drug on the market, the undelievered group will also usher in a double harvest of equity investment and product sales.
the market is generally concerned about the risk of research and development, Huang Jiangnan told reporters that antibody drugs have been proven to be a mature research and development direction, high certainty, research and development risk is relatively small. For BioAtla, this fourth-generation antibody drug is based on the original first and second-generation antibody drugs, which is expected to improve the tumor cure rate by 70%-80%.
bioAtla, the core technology for global patent applications, is the company's core competitiveness over its peers and the main driving force behind the move to attract international pharmaceutical giant Pfizer. In Pfizer's view, CAB technology is currently the best technology to develop immunotherapy drugs. Huang Jiangnan further said that the current U.S. drug from clinical to market cycle may be 5-8 years, but such antibody innovative drugs can be approved by the green channel can be shortened to 2-3 years approved for market. At that time, if the domestic approval of new drugs can speed up, the undelievered group is expected to be the first in China to be approved and listed for sale. (Sohu Securities)